Consistent with mRNA, MyD88 protein levels were also notably reduced by both MyD88 ASOs in tumor and more profoundly in adjacent non-tumor tissues, especially with the GalNAc-conjugated ASO when assessed by IHC (Figure 6D, top). This evidence concerns the gene MYD88 and neoplasm.